Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 43 for “"DLBCL"”.
-
Establishing the feasibility of using ctDNA for molecular profiling in DLBCL
DLBCL is a molecularly heterogeneous disease. Many clinical trials have failed to demonstrate improvements to survival by altering first line therapy. This may be due to failure to stratify patients in a way that reflects this molecular heterogeneity. Over the last 5 years, three large DLBCL …
-
Investigation of protein biomarkers in HIV positive and HIV negative associated DLBCL
Introduction: Diffused large B-cell lymphomas (DLBCL) is the most common aggressive nonHodgkin lymphoma (NHL) worldwide, constituting up to 40% of all cases globally. The incidence of HIV-associated lymphoma has decreased since the introduction of combination antiretroviral therapy (cART) in the …
-
Aqueous extracts of Dodonaea viscosa induce potent and selective cytotoxicity in DLBCL cells
… and females. Diffuse large B cell lymphoma (DLBCL), an aggressive B-cell derived cancer is the most prevalent cancer within the NHL group of cancers. DLBCL can be grouped into two main subtypes, namely the germinal-centre B cell (GCB) and the activated-B cell (ABC) subtypes, with the ABC …
-
Molecular characterisation of Diffuse large B-cell lymphomas (DLBCL) diagnosed at Groote Schuur Hospital (GSH)
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade neoplasm characterised by a diverse spectrum of clinical, morphological, immunophenotypic, and molecular features and response to therapy and survival. It is the most common lymphoma subtype diagnosed in South Africa. …
-
Molecular Characterisation of Diffuse Large B-cell Lymphoma in South Africa
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous and aggressive disease and is the most common subtype of non-Hodgkin lymphoma (NHL) in adults. Additionally, this subtype of lymphoma is also the most common in people infected with the Human Immunodeficiency virus (HIV), and the …
-
Biomarker identification in HIV and non-HIV related lymphomas
DLBCL is the most common lymphoma subtype occurring in older populations as well as in younger HIV infected patients. The current treatment options for DLBCL are effective for most patients yet the relapse rate is high. While many biomarkers for DLBCL exist, they are not in clinical use due to low …
-
Prognostic Markers and Mechanisms of Chemotherapy Resistance in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Identification of prognostic and predictive markers is important to design individualised and effective treatment strategies. This thesis describes different approaches to search for molecular prognostic markers and …
-
Programmed cell death-ligand 1 (PD-L1) expression in HIV-associated diffuse large B-cell lymphoma – role and regulation
Diffuse Large B cell Lymphoma (DLBCL) is an aggressive disease that displays striking heterogeneity at both the molecular and clinical levels; and as a result, up to 40% of patients relapse or are refractory to standard first-line therapy. DLBCL is the most common subtype of lymphoma affecting …
-
The Role of Pag1 In The Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma
<p>Diffuse Large B Cell Lymphoma (DLBCL) is the most common aggressive hematologic malignancy in adults, but despite recent advances in treatment, many patients today still face poor outcomes. Of the two types of DLBCL, activated B-cell (ABC) and germinal center B-cell (GCB), patients diagnosed …
-
Genetic Subclones Identify Phenotypic Variation in Diffuse Large B-Cell Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma. Many efforts have characterised DLBCL subtypes that account for some of the heterogeneity in clinical outcome following standard therapy. However, not much is known regarding intratumoural heterogeneity. Case …
-
Review of Diffuse large B cell lymphoma, pharmacological aspects of treatment and comparison of outcome between Pre-,Post Rituximab era
Diffuse large B Cell lymphoma (DLBCL) is a type aggressive non-Hodgkin Lymphoma (NHL). About 30% of patients who diagnosed NHL is DLBCL in both male and female. It is divided into 3 major types which distinct by immunological characteristics. It shall shows variable spectrum of prognosis and …
-
Analyse genomischer Aberrationen gastraler Marginalzonen B-Zell-Lymphome vom MALT-Typ
… „diffusen großzelligen B-Zell Lymphomen“ (DLBCL), jedoch besitzen diese DLBCL nicht die Translokation t(11;18)(q21;q21), die sich dagegen in den gastralen MZBCL vom MALT-Typ als die häufigste Translokation mit noch unklarer Konsequenz etablierte. Um die Pathogenese dieser Tumoren genauer zu …
-
Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: an analysis by cell-oforigin, Epstein-Barr virus infection and survival
… large B-cell lymphoma, not otherwise specified (DLBCL NOS) is subdivided according to the cell-of-origin (COO) classification into germinal centre B-cell (GCB) and activated B-cell (ABC) subtypes, each with different molecular profiles and clinical behaviour. This study aims to describe the …
-
Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most prevalent form of non-Hodgkin lymphoma is marked by significant heterogeneity in its morphology, genetic irregularities, and clinical behavior. Current prognostic tools, including the International Prognostic Index and cell-of-origin transcriptional …
-
DEVELOPMENT OF 4'-ETHYNYL-2'-DEOXYCYTIDINE (EdC), A REPLICATION-STRESS INDUCING NUCLEOSIDE ANALOG PRODRUG WITH PREFERENTIAL ACTIVITY IN LEUKEMIA AND LYMPHOMA SUBTYPES
… activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (dCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator. A 2.1Å …
-
Expression levels of miRNA-127 in a cohort of HIV-positive and HIV-negative Diffuse Large B-Cell Lymphoma.
… in South Africa due to the rise of HIV. DLBCL is quite an aggressive cancer but can be treated, however the relapse rate is high. There are prognostic indicators which can be seen as factors which can be indicative of a poor outcome for patients. Micro-RNA(miRNA) are small non-coding RNA …
-
EXPLORING THE MUTATIONAL LANDSCAPE OF MITOCHONDRIAL GENOME IN HEMATOLOGIC MALIGNANCIES
… patients with diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), alongside two cohorts of healthy donors. We identified 21, 19, and 16 disease-specific heteroplasmic mtDNA missense mutations in DLBCL, AML, and CLL, respectively. These …
-
Profilo molecolare dei linfomi post-trapianto
… 50 cases of diffuse large B-cell lymphomas (DLBCL) and 2 Burkitt lymphomas (BL). In order to evaluate the immune-profile a large panel of antibodies was applied including several new markers (Cyclin D2, Cyclin D3, p27, PKC-β, FOXP-1 and Survivin) identified as negative prognostic factors in …
-
Functional Drivers of Therapeutic Response in Diffuse Large B Cell Lymphoma
<p>Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma and a leading cause of death among B cell lymphomas. The disease displays a remarkable amount of genetic and clinical heterogeneity, hampering efforts at designing effective therapeutic agents. The last major …
-
Molecular Insights of Primary Thyroid B-cell Lymphomas by Somatic Genetic and Immunogenetic Profiling
… tissue (EMZL) and diffuse large B-cell lymphoma (DLBCL), followed by follicular lymphoma (FL). The Du group has previously shown that thyroid EMZL has a distinct mutation profile, characterised by frequent and often concurrent deleterious mutations in *TET2* (86%), *TNFRSF14* (53%) and *CD274* …
Page 1 of 3